extinct
发表于 2025-3-25 04:44:40
http://reply.papertrans.cn/43/4256/425544/425544_21.png
Rodent
发表于 2025-3-25 11:30:17
http://reply.papertrans.cn/43/4256/425544/425544_22.png
VICT
发表于 2025-3-25 15:03:34
http://reply.papertrans.cn/43/4256/425544/425544_23.png
opalescence
发表于 2025-3-25 18:42:26
http://reply.papertrans.cn/43/4256/425544/425544_24.png
或者发神韵
发表于 2025-3-25 21:03:43
http://reply.papertrans.cn/43/4256/425544/425544_25.png
Ptsd429
发表于 2025-3-26 00:45:13
http://reply.papertrans.cn/43/4256/425544/425544_26.png
AV-node
发表于 2025-3-26 07:10:35
http://reply.papertrans.cn/43/4256/425544/425544_27.png
BAIL
发表于 2025-3-26 12:09:58
http://reply.papertrans.cn/43/4256/425544/425544_28.png
persistence
发表于 2025-3-26 15:14:04
Novel Targeted Therapeutics for Acute Myeloid Leukemia, of clonal immature myeloid cells in the bone marrow, ultimately leading to hematopoietic failure. Despite some advances in therapy for patients with adult acute myeloid leukemia, the overall prognosis remains dismal. The backbone of induction therapy has not changed in decades, and usually includes
Ardent
发表于 2025-3-26 19:56:16
Novel Targeted Therapeutics for Peripheral T-Cell Lymphoma,ogical and molecular heterogeneity (Anderson et al. 1998). They are relatively rare diseases, constituting <15 % of all NHL’s (Groves et al. 2000). The present 2008 WHO classification recognizes over 20 sub-types of mature T-cell and NK-cell malignancies (WHO 2008). These sub-types are listed in Tab